AFMD - Affimed N V Stock Trading

AFM24 is an innate cell engager with a novel and distinctive mechanism of action, designed to address the need of broader patient populations than current EGFR-targeting treatments. Preclinical data demonstrate AFM24’s activation of the innate immune system, acting independen...

Whether penny stocks or blue-chips, analysts have high hopes for biotech stocks right now. Thanks to the growing optimism for new treatments & novel discoveries, this is one of the hottest industries in the stock market today. Does it come with plenty of risks? Of course, and this is on...

AFM13 monotherapy: Reported positive outcome from the preplanned interim analysis for the registration-directed trial in PTCL; enrollment expected to be completed in the first half of 2022. AFM13 combination with NK cells: Announced 100% objective response rate in the first four respo...